Jacobs Levy Equity Management’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-1,033,763
| Closed | -$519K | – | 1147 |
|
|
2024
Q4 | $519K | Buy |
+1,033,763
| New | +$519K | ﹤0.01% | 810 |
|
|
2023
Q1 | – | Sell |
-202,202
| Closed | -$237K | – | 1019 |
|
|
2022
Q4 | $237K | Sell |
202,202
-55,259
| -21% | -$64.7K | ﹤0.01% | 889 |
|
|
2022
Q3 | $291K | Buy |
+257,461
| New | +$291K | ﹤0.01% | 891 |
|
|
2018
Q3 | – | Sell |
-118,687
| Closed | -$214K | – | 1035 |
|
|
2018
Q2 | $214K | Buy |
118,687
+38,876
| +49% | +$70.1K | ﹤0.01% | 947 |
|
|
2018
Q1 | $188K | Sell |
79,811
-68,819
| -46% | -$162K | ﹤0.01% | 937 |
|
|
2017
Q4 | $280K | Sell |
148,630
-13,393
| -8% | -$25.2K | ﹤0.01% | 853 |
|
|
2017
Q3 | $403K | Buy |
162,023
+30,568
| +23% | +$76K | 0.01% | 737 |
|
|
2017
Q2 | $362K | Buy |
+131,455
| New | +$362K | 0.01% | 740 |
|